No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PepGen Stock Craters 35% on FDA Clinical Hold
Are Strong Financial Prospects The Force That Is Driving The Momentum In Entrada Therapeutics, Inc.'s NASDAQ:TRDA) Stock?
Roth MKM Starts 'Overlooked' Entrada Therapeutics With Buy Rating
Roth Initiates Entrada Therapeutics at Buy
H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $29